Corporate Venture Capital Firms in Europe

Accenture Ventures is the corporate venture capital arm of Accenture plc, a global professional services company. Established in 2015, the firm focuses on making strategic investments in early- and growth-stage technology companies. Its primary objective is to identify and partner with startups developing innovative enterprise and industry-focused technologies, integrating their capabilities into Accenture's extensive services and client solutions. This approach emphasizes strategic impact and accelerating product-market fit for its portfolio companies, leveraging Accenture's vast global client base and deep industry expertise.The firm's investment thesis centers on technologies that drive digital transformation and enhance enterprise capabilities. Key areas of focus include artificial intelligence (AI), cloud computing, cybersecurity, blockchain, data and analytics, and digital engineering. Accenture Ventures actively seeks out companies that can provide vertical AI solutions tailored to specific sectors such as financial services, healthcare, manufacturing, retail, and the public sector. They also explore emerging trends like physical AI and robotics, aiming to bridge the gap between groundbreaking ideas and scalable enterprise solutions.Accenture Ventures manages a $250 million fund and has made over 70 active venture investments. Notable portfolio companies include Replit, a platform for developing and deploying applications with AI; Sanctuary AI, a developer of AI-powered general-purpose robots; Open Cosmos, an operator of space missions providing satellite data; and Pixxel, which offers hyperspectral imaging satellites. The firm typically invests in Series A and Series B rounds, supporting startups through various stages of growth.The team at Accenture Ventures includes experienced professionals such as Tom Lounibos, Avnish Sabharwal, and Joe Lui. They bring a wealth of knowledge in technology and venture capital, working closely with portfolio companies to provide not just capital, but also strategic guidance, market access to Fortune Global 500 clients, and opportunities for co-innovation. The firm's global mandate allows it to invest across continents, emphasizing execution and local market understanding to support diverse innovation hubs.

Angelini Ventures is a prominent investment firm focused on the health technology and drug discovery sectors. With a strategic approach to venture capital, the firm aims to support innovative companies that are poised to make significant impacts in healthcare. Angelini Ventures is particularly interested in businesses that are developing cutting-edge technologies and solutions that enhance patient care and improve clinical outcomes. Angelini Ventures employs a rigorous investment strategy that emphasizes the importance of clinical validation and market demand. The firm targets companies that are at the intersection of hardware and software, particularly those that can leverage data analytics to enhance diagnostic capabilities. This focus is driven by the increasing need for non-invasive monitoring solutions in critical care settings, where traditional methods can be invasive and costly. Angelini Ventures is committed to fostering innovation in various sectors, including: Medtech: Investing in companies that develop medical devices and technologies that improve patient outcomes. Pharmaceuticals: Supporting drug discovery and development initiatives that address unmet medical needs. Digital Health: Focusing on solutions that enhance healthcare delivery through technology and data integration. Angelini Ventures has a clear vision of transforming healthcare through strategic investments that align with its core values of patient impact and system-level improvements. The firm recognizes the growing demand for advanced neuro-monitoring solutions as hospitals strive to reduce avoidable neurological complications and improve patient care efficiency. As the healthcare landscape continues to evolve, Angelini Ventures remains committed to identifying and supporting innovative companies that are poised to lead the charge in health technology. The firm’s strategic investments not only provide financial backing but also offer valuable insights and resources to help portfolio companies navigate the complexities of regulatory pathways and market entry. With a focus on delivering high-margin devices coupled with subscription or analytics services, Angelini Ventures is well-positioned to capitalize on the growing intersection of medtech and software-enabled diagnostics. The firm’s ability to provide continuous streams of validated physiological data opens up new licensing opportunities and partnerships within the healthcare ecosystem.

Aurorial is the corporate venture capital arm of PCComponentes, one of Spain’s leading online electronics retailers. Created to identify and invest in early-stage startups aligned with the strategic vision of PCComponentes, Aurorial focuses on innovation within e-commerce, logistics, supply chain optimization, and digital consumer experiences. The fund is part of the company's broader effort to foster entrepreneurship and technological advancement within its ecosystem. With a focus on collaboration, Aurorial not only provides funding but also strategic value by offering startups access to PCComponentes' expertise, distribution channels, and user base. It typically invests in seed and Series A rounds, targeting scalable technology solutions that can enhance operational efficiency, customer experience, or the broader value chain in e-commerce and retail. Aurorial acts as both an investor and a strategic partner, encouraging open innovation and long-term synergy. Aurorial primarily invests in startups based in Spain and Southern Europe but remains open to opportunities across Europe that present strong alignment with its core focus. As a forward-looking venture arm, it plays a key role in PCComponentes' mission to remain at the forefront of retail tech innovation while supporting the broader entrepreneurial ecosystem.

Btomorrow Ventures (BTV) is the corporate venture capital arm of British American Tobacco (BAT), established in 2020. The firm is dedicated to fostering world-class businesses that drive transformation and accelerate change, aligning with BAT's vision to build "A Better Tomorrow™" by reducing the health impact of its business and transitioning into a consumer-centric multi-category CPG company. BTV goes beyond mere financial investment, actively developing strategic partnerships with ambitious founders. It leverages the global distribution network and financial resources of BAT, spanning over 80 countries and 11 million points of sale, to combine corporate scale with startup innovation for accelerated growth.The firm's investment mandate is sharply focused on specialist categories, including consumer brands, digital transformation, new technologies, and future sciences, all underpinned by robust Environmental, Social, and Governance (ESG) criteria. BTV seeks out global founders and startups that can make a positive impact on BAT, its consumers, and the planet. This includes investments in functional food and beverage brands, emerging technologies, and innovative ESG solutions. BTV also operates various Labs, such as the Consumer Delight Lab, Futures Lab, and ESG Lab, to provide accelerated growth programs and industry-specific support.Btomorrow Ventures boasts a diverse portfolio of innovative companies. Notable investments include Actronika, which develops haptic technology; Awake, a producer of functional caffeinated chocolate; FlexSea, which develops compostable biopolymer materials from seaweed; Youvit, a leading Asian vitamin and functional gummy company; and Hesperos, involved in human-on-a-chip technology for drug discovery. The firm has also invested in companies like Bloom Biorenewables, which converts biomass into functional materials, and one.five, focused on sustainable packaging solutions. In December 2024, BTV launched its second fund with £200 million in committed capital, specifically targeting wellbeing and stimulation products to further support BAT's move beyond nicotine, with a focus on later-stage startups in Series B and Series C rounds.The BTV team comprises experienced professionals from various disciplines, bringing expertise in M&A, corporate finance, consumer packaged goods, and venture capital. Key team members include Annie Goman (Managing Director), Lukasz Garbowski (Chief Investment Officer), Fiona Kinghorn, Peter Wozny, Sam Morris, Karen Xiang, Yemo Guo, Emma-Jane Frost, Juan M. Palacios (MD), Letícia Boente, Jamie Price, Kory Sun, Joshua Galpin, Lexy Prosszer, Alice Smith, Deborah Lowther, Andrea McVeigh, Sarah Stapley, Tacio Cruz Solbes, Sarah Newnham, and Emily Arnett. Several team members have received industry recognition, such as Lukasz Garbowski being named a Global Top50 Emerging Leader by Global Corporate Venturing multiple times, and Juan M. Palacios receiving GCV’s highest accolade on behalf of BTV in 2024.

Ericsson Ventures is the corporate venture capital arm of Ericsson, a global leader in telecommunications and network technology. Founded in 2002, Ericsson Ventures invests in leading companies to drive innovation in new areas, accelerate Ericsson’s core business, and generate strong financial returns. The fund leverages Ericsson’s global reach, deep customer relationships, and industry expertise to support portfolio companies with strategic guidance, networking, and operational support. Ericsson Ventures focuses on emerging growth areas such as next-generation networking, artificial intelligence, IoT, cybersecurity, cloud computing, data analytics, and enterprise software. The firm invests across all stages, from early-stage to late-stage, and is active in North America, Europe, and select international markets. Its portfolio includes companies in biotechnology, cloud data services, communications infrastructure, and more, with a strong emphasis on technologies that align with Ericsson’s strategic vision and customer needs. Ericsson Ventures is led by experienced professionals with backgrounds in venture capital, private equity, and technology. The team includes José Suarez (Head of Ericsson Ventures), Paul McNamara, Graham Ackerman, Vik Li, and Porter Ontko. The firm is headquartered in Kista, Sweden, and maintains a robust network of co-investors and strategic partners, including major venture capital firms and industry leaders. Ericsson Ventures continues to play a pivotal role in shaping the future of connectivity and digital transformation.

Old College Capital (OCC) is the corporate venture arm of the University of Edinburgh, established in 2011. The firm functions as the university's venture investment fund, managing early-stage investment activities and shareholdings. Its primary mission is to support innovative ideas and technologies emerging from the University of Edinburgh, accelerating the journey of startups and spin-out companies that aim to make a positive impact on society and the planet. OCC operates with a long-term investment horizon, reinvesting its returns to foster the next generation of early-stage companies.The firm focuses on providing growth and development finance to early and mid-stage spin-out and start-up companies, often participating in syndicated venture capital rounds. Old College Capital employs a co-investment model, partnering with experienced private sector investors. Their investment strategy includes pre-seed initiatives, such as 'OCC Launch' with typical investments of £20k-£50k, and 'OCC Ventures' for Seed to Series A rounds, with typical cheque sizes ranging from £150k to £250k. They also manage the University's founding shareholdings in spin-outs through 'OCC Equity'.Old College Capital has a strong track record of investing in deep-tech sectors, including artificial intelligence, cleantech, agtech, biotechnology, medtech, therapeutics, semiconductors, and broader technology and life sciences. Notable investments include Carbogenics, a company in environmental services; MiAlgae, a circular economy business; Invizius, developing solutions for dialysis patients; Sunamp, a thermal energy storage company; and Bioliberty, a healthtech firm combining AI with soft-robotic wearable devices for physical rehabilitation.The team at Old College Capital comprises experienced deep-tech, early-stage investment specialists dedicated to translating university research and innovation into impactful ventures. Andrea, a founding team member, brings over 30 years of investment and venture capital experience. The team works collaboratively with founders, investors, and the broader University ecosystem, leveraging strong relationships with over 150 investors to help University of Edinburgh companies secure the right funding and expertise to flourish.

Pentland Ventures is the direct investment division of the Pentland Group, a family-owned business known for global brands like Speedo and Berghaus. The fund focuses on backing passionate entrepreneurs who are shaping the future by pioneering brands that improve life, particularly in health, wellness, and sustainability sectors. The firm invests primarily in early-stage companies, including pre-seed and seed rounds, with investment sizes ranging from $500,000 to $10 million. Their portfolio includes innovative startups in fitness, mental health platforms such as Unmind, enterprise software, health technology, and hiring and recruitment solutions. Pentland Ventures leverages its global reach and operational expertise to support startups in scaling and succeeding. Headquartered in London, Pentland Ventures operates as a corporate venture capital arm with a mission to invest in consumer brands and technologies that power the consumer economy. Their investment approach combines the conviction of a venture capital fund with the financial discipline of a private equity firm, focusing on sectors that promote health, sustainability, and innovation across Europe, North America, and other global markets.

Sanofi Ventures is the corporate venture capital arm of Sanofi, one of the world’s leading healthcare companies. The firm invests in early- to mid-stage biotech, digital health, and life sciences companies with innovative platforms and technologies that align with Sanofi’s core areas of interest. Sanofi Ventures provides strategic capital to entrepreneurs and companies transforming patient care through science and innovation. Founded in 2016, Sanofi Ventures builds long-term partnerships with companies pioneering advancements in immunology, oncology, rare diseases, vaccines, and digital health. While financially driven, the firm operates with a strategic lens, supporting companies that complement Sanofi’s internal R&D and therapeutic goals. The investment team brings deep expertise in science, operations, and company-building. Operating globally from offices in the U.S. and Europe, Sanofi Ventures backs visionary teams with the potential to create significant breakthroughs in healthcare. The firm typically participates in Seed, Series A, and Series B rounds, offering both capital and access to Sanofi’s global network, infrastructure, and expertise. With a collaborative approach, Sanofi Ventures helps portfolio companies navigate growth from concept to clinic.

T.Capital is the corporate venture capital arm of Deutsche Telekom, focused on providing early- and late-stage strategic capital to companies that align with Deutsche Telekom’s growth and innovation goals. The firm manages the full investment cycle—from origination to closing and beyond—while also supporting Deutsche Telekom in technology acquisitions and facilitating strategic partnerships. T.Capital invests across a broad range of sectors, with a particular emphasis on AI & cloud infrastructure, security, consumer technology, and connectivity. The firm leverages Deutsche Telekom’s global infrastructure, commercial resources, and extensive network to help portfolio companies scale and succeed. T.Capital’s investments are designed to create both strategic and financial value for Deutsche Telekom and its partners. T.Capital focuses on venture capital, growth equity, private equity, and buyout investments. Its target sectors include AI & Cloud Infrastructure, Security, Consumer Technology, Connectivity, Enterprise Software, Data, 5G, Internet of Things (IoT), Workflow Automation, Voice Synthesis, Speech AI, AI-Native Search, and the Global eSIM Marketplace. The firm operates primarily in North America, Europe, and Israel.